Kadcyla (trastuzumab‑emtansine)
Kadcyla is an antibody‑drug conjugate (ADC) that delivers a cytotoxic agent directly to HER2‑positive cancer cells. It combines the HER2‑specific monoclonal antibody trastuzumab with the microtubule‑inhibiting agent emtansine (DM1). Here’s a quick look at how it works and what the evidence says about its effectiveness.
| Topic | What you need to know |
|-------|-----------------------|
| Approved use | Kadcyla is approved for HER2‑positive metastatic breast cancer that has progressed on or after at least two prior anti‑HER2 therapies (trastuzumab ± pertuzumab, and a taxane). |
| Mechanism of action | Trastuzumab binds HER2 receptors on cancer cells, blocks receptor signaling, and flags cells for immune killing. When the antibody is taken up by the cell, the emtansine payload is released intracellularly, disrupting microtubules and inducing cell death. |
| Key clinical trials |
- EMILIA (NCT00942370) – Phase III comparing Kadcyla vs. lapatinib + capecitabine in patients previously treated with trastuzumab and a taxane. Kadcyla significantly improved progression‑free survival (PFS) (12.8 vs. 6.4 months) and overall survival (OS) (38.3 vs. 30.9 months).
- KATHERINE (NCT01444247) – Phase III comparing Kadcyla vs. trastuzumab after anthracycline‑taxane chemotherapy in early HER2‑positive breast cancer. Kadcyla reduced the risk of invasive disease recurrence by ~30 % (HR ≈ 0.70).
|
|
Efficacy in practice | •
Progression‑free survival: 12‑14 months in heavily pretreated metastatic setting.
•
Overall survival: 30‑38 months in the EMILIA trial.
•
Early‑stage adjuvant: 5‑year invasive disease–free survival ~90 % with Kadcyla vs. 80 % with trastuzumab alone in KATHERINE. |
|
Side‑effect profile | Common: peripheral neuropathy (≈15 %), nail changes, fatigue, nausea, vomiting, diarrhea.
Serious: cardiotoxicity (rare, especially when prior anthracyclines were used), interstitial lung disease, and liver enzyme elevations. Cardiac function is monitored by echocardiogram or MUGA scans every 3 months. |
|
What to watch for | •
Neuropathy – ask your oncologist about dose reductions or early treatment if you feel numbness or tingling.
•
Cardiac status – keep track of your LVEF; report symptoms of shortness of breath or fatigue promptly.
•
Drug interactions – avoid grapefruit juice and other CYP3A4 inhibitors that could increase emtansine exposure. |
|
Real‑world data | In the 2023 real‑world registry, Kadcyla retained its PFS advantage over lapatinib‑capecitabine while offering a more favorable safety profile. The rate of neuropathy was comparable to EMILIA, but fewer patients required treatment discontinuation. |
Bottom line
Kadcyla is a highly targeted therapy that has shown clear survival benefits in HER2‑positive breast cancer patients who have progressed on prior HER2 agents. Its efficacy is backed by two pivotal Phase III trials (EMILIA and KATHERINE), and it remains the standard of care in the metastatic setting after trastuzumab/pertuzumab and taxane therapy. If you’re considering Kadcyla or are already on it, discuss your cardiac function, neuropathy symptoms, and any other meds with your oncology team to keep the therapy both effective and safe.